Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SCD | O00767 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578078 | 0.77 | YAP1 (0.55) | MEN1KMT2ASCDEPHX2CARM1 | |
| SCHEMBL10313329 | 0.75 | KMT2A (0.67) | MEN1KMT2ASCDNAMPT | |
| SCHEMBL9013996 | 0.75 | KEAP1 (0.49) | — | |
| SCHEMBL11022779 | 0.73 | KMT2A (0.56) | MEN1KMT2AEPHX2NPC1RAB9A | |
| SCHEMBL9013850 | 0.73 | NAMPT (0.49) | EPHX2NAMPT | |
| SCHEMBL4577340 | 0.73 | SCD (0.56) | SCDEPHX2NAMPTRAB9A | |
| SCHEMBL20857043 | 0.73 | YAP1 (0.50) | KMT2ASCDEPHX2CARM1PRMT6 | |
| SCHEMBL9014112 | 0.73 | OPRK1 (0.53) | MEN1KMT2ACARM1PRMT6NPC1 | |
| SCHEMBL2091338 | 0.72 | EPHX2 (0.57) | EPHX2CARM1PRMT6NAMPT | |
| SCHEMBL12450862 | 0.72 | ALDH1A1 (0.57) | SCDEPHX2NAMPTCYP2C9CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009060452-A2 | METHODS AND COMPOSITIONS FOR TREATING BILIARY CHOLESTEROL CRYSTALLIZATION AND RELATED CONDITIONS | GALMED INTERNATIONAL LTD. (MT) | 2009-05-14 | — | — | WO | claimed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| EP-2398809-B1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014091048-A1 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER | FUNDACIÓN IMDEA ALIMENTACIÓN (ES) | 2014-06-19 | — | — | WO | disclosed |
| CN-101516877-B | Heterocyclic organic compounds | NOVARTIS AG | 2013-09-11 | — | — | CN | disclosed |
| US-8383643-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-2459568-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Limited (CA) | 2012-06-06 | — | — | EP | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010037225-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
| EP-2152719-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009129625-A1 | NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-10-29 | — | — | WO | disclosed |
| CN-101516877-A | Heterocyclic organic compounds | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| WO-2009073973-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009060452-A2 | METHODS AND COMPOSITIONS FOR TREATING BILIARY CHOLESTEROL CRYSTALLIZATION AND RELATED CONDITIONS | GALMED INTERNATIONAL LTD. (MT) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009012573-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008141455-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | MEN1 2780/4885KMT2A 2541/4885SCD 1194/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | MEN1 2780/4885KMT2A 2541/4885SCD 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.